PsychedelicNewsBreaks Archive - Page 25 of 70

WednesdayMay 18, 2022 12:15 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Share Expansion Strategy at H.C. Wainwright Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding participation of its CEO Matt Stang at the H.C. Wainwright Annual Global Life Sciences Conference taking place May 23-26, 2022, in Miami, Florida. The four-day event will feature keynote presentations, investor one-on-one meetings, networking opportunities and evening entertainment. At this year's conference, Stang will present the company's expansion strategy and participate in one-on-one meetings. Interested parties should visit https://ibn.fm/UGjjp to register for the event. To view the full press release, visit https://ibn.fm/EkzBY About Delic Holdings Corp. Delic…

TuesdayMay 17, 2022 2:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments…

MondayMay 16, 2022 2:37 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the announcement, Delic is experiencing delays to its audit, which means that the required annual financial statements and management's discussion and analysis for FY 2021 have been delayed as well. The company had requested that a management cease trade order (“MCTO”) be imposed as a result…

ThursdayMay 12, 2022 12:29 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Enters New VA Partnership in Arizona

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (“VA”) in Arizona. Per the update, veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at KWC Arizona clinics located in Phoenix, Tucson and Mesa - Gilbert at no out-of-pocket cost with prior authorization from the VA. This new VA partnership is in addition to the one established with the Burnsville, Minnesota-based KWC. “At KWC, we take great pride in supporting our…

WednesdayMay 11, 2022 11:18 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/34DNj…

WednesdayMay 11, 2022 11:10 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the search box. Anthony Durkacz, interim CEO and co-executive chairman of FSD Pharma, said of the move: “This is a major accomplishment and puts us in a good position going forward especially considering the current state…

TuesdayMay 10, 2022 2:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several days after administration. Specifically, Kernel Flow successfully measured the neuro-effect of ketamine over 11 days (baseline at Days 1-5, dosing at Day 6, follow-up at Days 7-11); in addition, the results confirmed changes in functional…

TuesdayMay 10, 2022 2:09 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering the current state of the capital markets. While most companies have taken huge write-downs on dispositions of cannabis-related assets, we were able to net significant profit from selling the facility,” said Anthony Durkacz, interim CEO…

FridayMay 06, 2022 2:15 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study

Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other conditions,’ and the company’s joint homing peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, ‘enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic…

ThursdayMay 05, 2022 2:55 pm

PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks